Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative
- Author
- Tine Cuppens, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel Garcia-Jimenez, Koen Van de Vijver (UGent) , Roy PM Kruitwagen, Mariel Brinkhuis, Michal Zikan, Pavel Dundr, Jutta Huvila, Olli Carpen, Johannes Haybaeck, Farid Moinfar, Helga B Salvesen, Maciej Stukan, Carole Mestdagh, Ronald P Zweemer, Leonardus F Massuger, Michael R Mallmann, Eva Wardelmann, Miriam Mints, Godelieve Verbist, Debby Thomas, Ellen Gomme, Els Hermans, Philippe Moerman, Tjalling Bosse and Frederic Amant
- Organization
- Keywords
- ENDOMETRIAL STROMAL SARCOMA, SOFT-TISSUE SARCOMA, GROWTH-FACTOR RECEPTOR, AKT-MTOR PATHWAY, MAMMALIAN TARGET, BREAST-CANCER, CYCLIN D1, EXPRESSION, TUMORS, TRIAL
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 1.00 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8578031
- MLA
- Cuppens, Tine, et al. “Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas : An ENITEC Group Initiative.” CLINICAL CANCER RESEARCH, vol. 23, no. 5, 2017, pp. 1274–85, doi:10.1158/1078-0432.CCR-16-2149.
- APA
- Cuppens, T., Annibali, D., Coosemans, A., Trovik, J., ter Haar, N., Colas, E., … Amant, F. (2017). Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative. CLINICAL CANCER RESEARCH, 23(5), 1274–1285. https://doi.org/10.1158/1078-0432.CCR-16-2149
- Chicago author-date
- Cuppens, Tine, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel Garcia-Jimenez, et al. 2017. “Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas : An ENITEC Group Initiative.” CLINICAL CANCER RESEARCH 23 (5): 1274–85. https://doi.org/10.1158/1078-0432.CCR-16-2149.
- Chicago author-date (all authors)
- Cuppens, Tine, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel Garcia-Jimenez, Koen Van de Vijver, Roy PM Kruitwagen, Mariel Brinkhuis, Michal Zikan, Pavel Dundr, Jutta Huvila, Olli Carpen, Johannes Haybaeck, Farid Moinfar, Helga B Salvesen, Maciej Stukan, Carole Mestdagh, Ronald P Zweemer, Leonardus F Massuger, Michael R Mallmann, Eva Wardelmann, Miriam Mints, Godelieve Verbist, Debby Thomas, Ellen Gomme, Els Hermans, Philippe Moerman, Tjalling Bosse, and Frederic Amant. 2017. “Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas : An ENITEC Group Initiative.” CLINICAL CANCER RESEARCH 23 (5): 1274–1285. doi:10.1158/1078-0432.CCR-16-2149.
- Vancouver
- 1.Cuppens T, Annibali D, Coosemans A, Trovik J, ter Haar N, Colas E, et al. Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative. CLINICAL CANCER RESEARCH. 2017;23(5):1274–85.
- IEEE
- [1]T. Cuppens et al., “Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative,” CLINICAL CANCER RESEARCH, vol. 23, no. 5, pp. 1274–1285, 2017.
@article{8578031,
author = {{Cuppens, Tine and Annibali, Daniela and Coosemans, An and Trovik, Jone and ter Haar, Natalja and Colas, Eva and Garcia-Jimenez, Angel and Van de Vijver, Koen and Kruitwagen, Roy PM and Brinkhuis, Mariel and Zikan, Michal and Dundr, Pavel and Huvila, Jutta and Carpen, Olli and Haybaeck, Johannes and Moinfar, Farid and Salvesen, Helga B and Stukan, Maciej and Mestdagh, Carole and Zweemer, Ronald P and Massuger, Leonardus F and Mallmann, Michael R and Wardelmann, Eva and Mints, Miriam and Verbist, Godelieve and Thomas, Debby and Gomme, Ellen and Hermans, Els and Moerman, Philippe and Bosse, Tjalling and Amant, Frederic}},
issn = {{1078-0432}},
journal = {{CLINICAL CANCER RESEARCH}},
keywords = {{ENDOMETRIAL STROMAL SARCOMA,SOFT-TISSUE SARCOMA,GROWTH-FACTOR RECEPTOR,AKT-MTOR PATHWAY,MAMMALIAN TARGET,BREAST-CANCER,CYCLIN D1,EXPRESSION,TUMORS,TRIAL}},
language = {{eng}},
number = {{5}},
pages = {{1274--1285}},
title = {{Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative}},
url = {{http://doi.org/10.1158/1078-0432.CCR-16-2149}},
volume = {{23}},
year = {{2017}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: